What are the different clinical and serologic types of antiphospholipid syndrome?

Types of Antiphospholipid Syndrome

Antiphospholipid syndrome is classified into distinct serologic risk profiles based on antibody patterns (triple-positive, double-positive, or single-positive) and clinical phenotypes (thrombotic, obstetric, and skin-CNS-cardiac), with triple-positive patients carrying the highest risk for thrombotic events and recurrence. 1

Serologic Classification by Antibody Profile

The most clinically relevant classification system stratifies APS by the number and type of persistently positive antiphospholipid antibodies:

Triple-Positive APS (Highest Risk)

• Positive for all three criteria antibodies: lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I (aβ2GPI) with concordant isotype
• Associated with 90% presenting with clinical APS criteria 1
• Carries the highest risk for first thrombotic events and recurrence 1, 2
• Strongest predictor across all clinical manifestations 1

Double-Positive APS (Intermediate Risk)

• Two of three criteria antibodies positive (most commonly LA-negative with aCL and aβ2GPI positive with concordant isotype)
• 86% present with clinical APS criteria 1
• Intermediate thrombotic risk profile 1
• The β2GPI level may be insufficient to induce LA positivity in these patients 2

Single-Positive APS (Variable Risk)

• Only one criteria antibody persistently positive
• Isolated LA: Despite debate, strongly associated with thrombosis and mortality independent of other antibodies 1; receives high weight in 2023 ACR/EULAR criteria 1; strongest predictor for pregnancy morbidity 1
• Isolated aCL: Contradictory data; may reflect antibodies to cardiolipin itself rather than β2GPI-dependent antibodies 1; lower weight in classification criteria 1
• Isolated aβ2GPI: Shows no association with thrombosis; directed against non-pathogenic epitopes 1

Clinical Phenotype Classification

Recent hierarchical cluster analysis of 1,435 APS patients identified three distinct clinical phenotypes 3:

1. Obstetric Phenotype

• Predominant pregnancy morbidity manifestations
• Recurrent fetal loss, late pregnancy complications
• LA positivity is the strongest risk factor, with LA + aβ2GPI combination showing highest predictive value 1

2. Venous Thrombosis Phenotype

• Largest patient group in both validation cohorts 3
• Predominantly venous thrombotic events
• Deep vein thrombosis, pulmonary embolism

3. Skin-CNS-Cardiac Phenotype

• Preferential association of cutaneous, neurological, and cardiac manifestations
• Includes livedo reticularis, stroke, myocardial infarction, valvular disease
• More complex multi-organ involvement pattern 3

Primary vs. Secondary Classification

Primary APS

• 53.1% of patients 4
• Occurs as isolated condition without underlying autoimmune disease
• Same clinical manifestations as secondary APS

Secondary APS

• 36.2% associated with systemic lupus erythematosus (SLE) 4
• 5.0% with lupus-like syndrome 4
• 5.9% with other autoimmune diseases 4
• Patients with SLE-associated APS have higher frequency of arthritis, livedo reticularis, thrombocytopenia, and leukopenia 4

Special Subtypes

Catastrophic APS

• Rare variant affecting 0.8% of patients 4
• Acute multi-organ thrombotic failure
• Medical emergency requiring aggressive treatment 5

Microvascular APS

• Distinct from macrovascular thrombotic disease
• Involves small vessel thrombosis and microvascular dysfunction 5
• Different mechanistic emphasis on endothelial and complement activation 5

Critical Clinical Considerations

All three antibody tests (LA, aCL, aβ2GPI) must be performed concurrently on the same sample to accurately determine the antibody profile and risk stratification 1. The antibody profile directly informs prognosis and management decisions, with triple-positive patients requiring more aggressive anticoagulation strategies.

Persistence is mandatory: Positive antibodies must be confirmed on repeat testing at least 12 weeks apart to distinguish true APS from transient antibody positivity associated with infections or medications 1, 2.

The clinical phenotype does not correlate with antibody profile—patients across all three clinical phenotypes show similar distributions of antibody positivity patterns 3. This emphasizes that both serologic classification and clinical phenotype recognition are necessary for comprehensive APS characterization.